{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:00:05Z","timestamp":1783443605727,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106311","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:30:08Z","timestamp":1740047408000},"page":"106311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-4937","authenticated-orcid":false,"given":"Gabriel de Deus","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius Oliveira","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.msard.2025.106311_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1166490","article-title":"Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis","volume":"14","author":"Aungsumart","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106311_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton","year":"2022","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40120-024-00597-7","article-title":"Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder","volume":"13","author":"Clardy","year":"2024","journal-title":"Neurol. Ther."},{"issue":"10206","key":"10.1016\/j.msard.2025.106311_bib0006","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2025.106311_bib0007","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106311_bib0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.neurol.2024.06.003","article-title":"Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: cost and efficacy considerations","volume":"180","author":"Deschamps","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"issue":"6176","key":"10.1016\/j.msard.2025.106311_bib0009","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"14","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.msard.2025.106311_bib0010","article-title":"The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106311_bib0011","unstructured":"Food and Drug Administration (2021) TAVNEOS (avacopan) capsules, for oral use. Accessed 13 Jul 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214487s000lbl.pdf."},{"key":"10.1016\/j.msard.2025.106311_bib0012","unstructured":"Food and Drug Administration (2023) Zilbrysq NDA approval. Accessed 08 Jul 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/216834Orig1s000ltr.pdf."},{"key":"10.1016\/j.msard.2025.106311_bib0013","unstructured":"Food and Drug Administration, 2024. ULTOMIRIS\u00ae (ravulizumab-cwvz) injection, for intravenous use. Accessed 10 Jul 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf."},{"issue":"1","key":"10.1016\/j.msard.2025.106311_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40478-022-01416-6","article-title":"C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer's disease","volume":"10","author":"Gomez-Arboledas","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.msard.2025.106311_bib0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-017-0210-z","article-title":"Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss","volume":"12","author":"Hernandez","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"11","key":"10.1016\/j.msard.2025.106311_bib0016","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus Eculizumab in Paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106311_bib0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106311_bib0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/2051-5960-2-53","article-title":"Complement activation in multiple sclerosis plaques: an immunohistochemical analysis","volume":"2","author":"Ingram","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"7","key":"10.1016\/j.msard.2025.106311_bib0019","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2025.106311_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"1","key":"10.1016\/j.msard.2025.106311_bib0021","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00281-014-0424-x","article-title":"B cells in MS and NMO: pathogenesis and therapy","volume":"36","author":"Krumbholz","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.msard.2025.106311_bib0023","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jmsacl.2021.08.002","article-title":"Ravulizumab: characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry","volume":"21","author":"Ladwig","year":"2021","journal-title":"J. Mass. Spectrom.Adv. Clin. Lab."},{"issue":"1","key":"10.1016\/j.msard.2025.106311_bib0024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14712598.2020.1725468","article-title":"Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Lee","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"9451","key":"10.1016\/j.msard.2025.106311_bib0026","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2025.106311_bib0027","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bpa.12546","article-title":"Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis","volume":"28","author":"Loveless","year":"2018","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.msard.2025.106311_bib0028","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.msard.2025.106311_bib0029","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/1352458512471875","article-title":"Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders","volume":"19","author":"Lim","year":"2013","journal-title":"Multiple Scler."},{"issue":"Pt 7","key":"10.1016\/j.msard.2025.106311_bib0030","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain: J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106311_bib0031","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2025.106311_bib0032","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 water channel in the brain and its implication for health and disease","volume":"27","author":"Mader","year":"2019","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.msard.2025.106311_bib57","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300648120","article-title":"Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein","volume":"120","author":"Mader","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0033","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0034","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/WCO.0000000000001052","article-title":"Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond","volume":"35","author":"Mader","year":"2022","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106311_bib0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106311_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101645","article-title":"Recent developments in C3-targeted complement therapeutics","volume":"60","author":"Mastellos","year":"2022","journal-title":"Semin. Immunol."},{"issue":"27","key":"10.1016\/j.msard.2025.106311_bib0037","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.msard.2025.106311_bib56","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9ventio, 2019. Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques publi\u00e9s en application des articles L. 162-16-5 et L. 162-16-6 du code de la s\u00e9curit\u00e9 sociale. J. Off. Republ. Fran\u00e7a. Text 89 from 120. Accessed 06 Feb 2025. https:\/\/www.legifrance.gouv.fr\/download\/pdf?id=8LHrVj2snUH7vrwi7JViLoXAjIGsp5eVn7t7MU3Af7o=."},{"key":"10.1016\/j.msard.2025.106311_bib0038","article-title":"Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques publi\u00e9s en application de l'article L. 162-16-6 du code de la s\u00e9curit\u00e9 sociale","year":"2023","journal-title":"J. Off. Republ. Fran\u00e7a"},{"key":"10.1016\/j.msard.2025.106311_bib0039","article-title":"An \u201cOutside-In\u201d and \u201cInside-Out\u201d consideration of complement in the multiple sclerosis brain: lessons from development and neurodegenerative diseases","author":"Morgan","year":"2020","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.msard.2025.106311_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1020580","article-title":"Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b","volume":"13","author":"Muri","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106311_bib0041","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.26137","article-title":"Swiss Multiple sclerosis cohort study. Intrathecal immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis","volume":"90","author":"Oechtering","year":"2021","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106311_bib0042","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200212","article-title":"Complement activation is associated with disease severity in multiple sclerosis","volume":"11","author":"Oechtering","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2025.106311_bib0043","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106311_bib0044","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106311_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209888","article-title":"Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort","volume":"103","author":"Ringelstein","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106311_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","article-title":"Zilucoplan: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.msard.2025.106311_bib0046","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.msard.2025.106311_bib0047","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106311_bib0048","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol. Sci.: Off. J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2025.106311_bib0049","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in Myasthenia Gravis: a review of the current evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatr. Dis. Treatm."},{"issue":"1","key":"10.1016\/j.msard.2025.106311_bib0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12974-016-0611-x","article-title":"Complement is activated in progressive multiple sclerosis cortical grey matter lesions","volume":"13","author":"Watkins","year":"2016","journal-title":"J. Neuroinfl."},{"key":"10.1016\/j.msard.2025.106311_bib0051","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Wingerchuk","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2025.106311_bib0052","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"22","key":"10.1016\/j.msard.2025.106311_bib0053","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis Optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106311_bib0054","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:46Z","timestamp":1741841326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":56,"alternative-id":["S2211034825000550"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106311","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106311"}}